{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:24Z","timestamp":1792788204259,"version":"4.5.0"},"reference-count":13,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Elranatamab, approved for relapsed or refractory multiple myeloma, demonstrated deep, durable responses and manageable safety in patients without prior B\u2010cell maturation antigen (BCMA)\u2010directed therapy (BCMA\u2010naive) in MagnetisMM\u20103 (NCT04649359). This post hoc analysis evaluated efficacy and safety in the US subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following step\u2010up dosing, patients received 28\u2010day cycles of elranatamab 76 mg once weekly. After \u22656 cycles, patients with partial response or better persisting for \u22652 months transitioned to every 2 weeks, then to every 4 weeks after \u22656 every\u20102\u2010week cycles. This analysis included all US\u2010enrolled BCMA\u2010naive patients who received \u22651 elranatamab dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 123 evaluable patients, 47 were enrolled in the United States (38.2%). At a median follow\u2010up of 39.6 months, the objective response rate was 66.0% (95% CI, 50.7\u201379.1); 42.6% (95% CI, 28.3\u201357.8) achieved complete response or better. Median (95% CI) duration of response, progression\u2010free survival, and overall survival were 40.8 (24.0\u2013not estimable [NE]), 27.3 (4.3\u2013NE), and 43.6 (14.9\u2013NE) months, respectively. Common (\u226560%) treatment\u2010emergent adverse events (any grade; grade 3\/4) included infections (70.2%; 42.6%), fatigue (61.7%; 8.5%), and cytokine release syndrome (61.7%; 0%). Twenty\u2010two patients switched from once weekly to every\u20102\u2010week dosing, then eight switched from every\u20102\u2010week to every\u20104\u2010week dosing. Of 18 responders who switched from once weekly to every\u20102\u2010week dosing and eight responders who further reduced to every 4 weeks, 77.8% and 87.5%, respectively, maintained or improved their response for \u22656 months thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elranatamab demonstrated durable responses and manageable safety in the heavily pretreated US subgroup, consistent with the overall MagnetisMM\u20103 BCMA\u2010naive population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70442","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:25:38Z","timestamp":1779272738000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM\u20103"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"first","affiliation":[{"name":"Winship Cancer Institute  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Blood &amp; Marrow Transplantation University of Iowa  Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Larson","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology UCLA School of Medicine  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lesokhin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asya","family":"Varshavsky\u2010Yanovsky","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center  Hackensack New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther","family":"Koehne","sequence":"additional","affiliation":[{"name":"Blood &amp; Marrow Transplant and Hematologic Oncology Miami Cancer Institute  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpitha","family":"Soussou","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon T.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-1568","authenticated-orcid":false,"given":"Jay","family":"Cheng","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002528\u20109"},{"key":"e_1_2_12_3_1","volume-title":"Prescribing information","author":"Elrexfio (elranatamab\u2010bcmm)","year":"2025"},{"key":"e_1_2_12_4_1","unstructured":"Elrexfio (elranatamab) Summary of product characterstics.2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/elrexfio\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_12_5_1","volume-title":"Package insert","author":"Elrexfio (elranatamab)","year":"2024"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010208192"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970332.39705.0f"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001206\u20104"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000877\u20109"},{"issue":"1","key":"e_1_2_12_11_1","first-page":"1191","article-title":"Long\u2010term follow\u2010up from the China cohort of the phase 1\/2 MajesTEC\u20101 study of teclistamab (TEC) treatment in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"9","author":"Cai Z","year":"2025","journal-title":"HemaSphere"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_12_14_1","volume-title":"4738 MagnetisMM\u20103: long\u2010term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma","author":"Prince HM","year":"2024"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:06:27Z","timestamp":1784297187000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1002\/cncr.70442"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70442","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"2026-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70442"}}